Why the study?
The safety and efficacy of novel oral anticoagulants compared to warfarin after TAVR remain uncertain despite risks of thromboembolic events and leaflet thrombosis.
Meta-Analysis
Meta-analysis and trial sequential analysis evaluates novel oral anticoagulants versus warfarin after transcatheter aortic valve replacement, highlighting stroke and leaflet thrombosis risks.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Sethi et al. (2025) conducted a meta-analysis in Transcatheter aortic valve replacement (TAVR). Novel oral anticoagulants (NOACs) vs. Warfarin was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: